Literature DB >> 33608328

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.

Geremia B Bolli1, Francesca Porcellati2, Paola Lucidi2, Carmine G Fanelli2.   

Abstract

Entities:  

Year:  2021        PMID: 33608328     DOI: 10.2337/dc20-2575

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  1 in total

1.  Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.

Authors:  Klara R Klein; Schafer C Boeder; Jennifer L R Freeman; Imogene Dunn; Chris Dvergsten; Supradeep Madduri; Erin R Giovannetti; Carmen Valcarce; John B Buse; Jeremy H Pettus
Journal:  Diabetes Obes Metab       Date:  2022-06-04       Impact factor: 6.408

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.